Marker Therapeutics Reports Q4 EPS of -$0.79, Revenue of $3.55M

miércoles, 18 de marzo de 2026, 6:15 pm ET1 min de lectura
MRKR--

Marker Therapeutics reported a GAAP EPS of -$0.79, beating estimates by $0.15. Revenue was $3.55M, a decrease of 46.1% YoY, but still beat estimates by $0.45M.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios